Already in January 2013 the U.S. FDA issued a Safety Warning for the hypnotic zolpidem. According to the statement, overhang effects are possible in the morning after intake of zolpidem, which can lead to impaired performance of activities that require full attention and alertness (eg, driving). Particularly vulnerable are women, because they metabolize the substance slowly. Continue reading
A few days ago, the European Medicines Agency EMA has approved the opioid receptor antagonist nalmefene for the treatment of alcohol dependence. The substance will be marketed as Selincro® in Germany, manufacturer is the Danish company Lundbeck.
Nalmefene is not the first opioid receptor antagonist available for the treatment of alcohol dependence. Continue reading
On February 18th, 2013, the German ARD broadcasted the program “Dangerous happy pills – billions in profits with antidepressants”. In that broadcast it is stated that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or paroxetine, may cause suicidal behavior, aggression and violence. Continue reading
End of February, the European Medicines Agency EMA has approved the first inhalant antipsychotic medication, Adasuve. The FDA had approved it already in December 2012. Manufacturer is the American company Alexza Pharmaceuticals, sales in Europe takes the Spanish Ferrer Group. The approval covers the “rapid control of mild to moderate agitation in adults with schizophrenia or bipolar disorder”. Continue reading